Kathryn L. Hassell, MD has been the Director of the Colorado Sickle Cell Treatment and Research Center at the University of Colorado since 2003, after serving as its associate Director since 1992. She is also a Professor of Medicine at the University of Colorado, School of Medicine. Much of Dr. Hassell’s work surrounds sickle cell disease and her scientific interests include coagulation disorders like antiphospholipid antibody syndrome and heparin-induced thrombocytopenia, investigation of novel anticoagulant therapies and strategies, hemoglobinopathies/sickle cell disease including mechanisms of vascular injury and chronic organ damage.
Dr. Hassell earned her medical degree from the University of Minnesota Medical School. She then went on to complete her Hematology- Oncology fellowship at the University of Colorado Health Science Center, where she has continued to work as a researcher and professor. She has helped lead several regional projects through the Mountain States Genetics Regional Collaborative Center (MSGRC), and serves on the Newborn Screening Advisory Committee for Colorado State Department of Health. She also serves on various committees including the Sickle Cell Disease Treatment Demonstration Project for HRSA, the American Society of Hematology’s Public Health Taskforce, and the Registries and Surveillance for Hemoglobinopathies (RuSH) Project for the CDC and NIH. In addition to her duties, she recently completed a four-year, part-time, IPA assignment with the National Heart, Lung and Blood Institute (NHLBI). Dr. Hassell currently serves as Associate Project Director of the Mountain States Genetics Regional Collaborative.
In over her 20 years at CU, Dr. Hassell has helped contribute to more than 50 peer reviewed articles and has been invited to give countless presentations at various institutions. The NBSTRN is pleased to honor Dr. Hassell for her valuable work towards both the sickle cell and newborn screening communities!